Secondary Prevention in Patients Several Years after Myocardial Infarction: Comparison of an Outpatient and an Inpatient Rehabilitation Programme
暂无分享,去创建一个
[1] H A Dewar,et al. The primary prevention of myocardial infarction. , 2009, Scandinavian journal of haematology. Supplementum.
[2] D. Stewart,et al. Cardiac rehabilitation II: referral and participation. , 2002, General hospital psychiatry.
[3] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[4] G. Mancia,et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. , 1998, Atherosclerosis.
[5] S Goya Wannamethee,et al. Changes in physical activity, mortality, and incidence of coronary heart disease in older men , 1998, The Lancet.
[6] N. Campbell,et al. Secondary prevention clinics for coronary heart disease: randomised trial of effect on health , 1998, BMJ.
[7] D Kromhout,et al. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. , 1997, European heart journal.
[8] M. Laakso,et al. Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. , 1997, Atherosclerosis.
[9] K. Pyörälä. CHD prevention in clinical practice , 1996, The Lancet.
[10] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[11] C. Blauth,et al. Prevention and management of cardiovascular disease in patients with diabetes mellitus: an evidence base. , 1996, Diabetic medicine : a journal of the British Diabetic Association.
[12] T. Bowker,et al. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). , 1996, Heart.
[13] D. Brand,et al. Cardiologists' practices compared with practice guidelines: use of beta-blockade after acute myocardial infarction. , 1995, Journal of the American College of Cardiology.
[14] J. Cutler,et al. Blood Pressure and Mortality Among Men With Prior Myocardial Infarction , 1995 .
[15] V. Fuster,et al. Preventing heart attack and death in patients with coronary disease. , 1995, Circulation.
[16] R S Paffenbarger,et al. Changes in physical fitness and all-cause mortality. A prospective study of healthy and unhealthy men. , 1995, JAMA.
[17] V. Bittner. Primary and secondary prevention of ischemic heart disease. , 1994, Current opinion in cardiology.
[18] P. Touboul,et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease , 1994, The Lancet.
[19] D. Rogers,et al. Literature Reviews: Endocrinology , 1994 .
[20] Walker,et al. Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .
[21] L. Valenti,et al. Secondary prevention after acute myocardial infarction. , 1993, The American journal of cardiology.
[22] R S Paffenbarger,et al. The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. , 1993, The New England journal of medicine.
[23] K. Swedberg,et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) , 1992, The New England journal of medicine.
[24] R. D'Agostino,et al. Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham Study. , 1991, BMJ.
[25] P. Elwood,et al. EFFECTS OF CHANGES IN FAT, FISH, AND FIBRE INTAKES ON DEATH AND MYOCARDIAL REINFARCTION: DIET AND REINFARCTION TRIAL (DART) , 1989, The Lancet.
[26] J. Paniagua,et al. [Cholesterol and high-density lipoprotein cholesterol in acute myocardial infarct]. , 1988, Medicina clinica.
[27] R. Peto,et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.
[28] S. Taylor. Secondary Prevention After Myocardial Infarction: Facts and Fallacies , 1984, Journal of cardiovascular pharmacology.
[29] R. J. Bondar,et al. Evaluation of glucose-6-phosphate dehydrogenase from Leuconostoc mesenteroides in the hexokinase method for determining glucose in serum. , 1974, Clinical chemistry.
[30] P. Fu,et al. Enzymatic determination of total serum cholesterol. , 1974, Clinical chemistry.
[31] G Bucolo,et al. Quantitative determination of serum triglycerides by the use of enzymes. , 1973, Clinical chemistry.
[32] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.
[33] E. C. Hammond,et al. Coronary heart disease, stroke, and aortic aneurysm. , 1969, Archives of environmental health.
[34] C. Gohlke-Bärwolf,et al. Cardiac rehabilitation: where are we going? , 1998, European heart journal.
[35] Philippe Amouyel,et al. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. , 1997 .
[36] J. Cruickshank. Beta-blockers: primary and secondary prevention. , 1992, Journal of cardiovascular pharmacology.